1-8 of 8
Sahra Ali
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Michael Dennis, MDMRCP,FRCPath, Robert K. Hills, DPhil, Nigel H. Russell, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Ian Thomas, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Sahra Ali, Alan K. Burnett, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3874.
https://doi.org/10.1182/blood.V130.Suppl_1.3874.3874
Published: 2017
Journal Articles

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Dragana Milojkovic, MBBS, PhD, Richard E. Clark, Jennifer L Byrne, Brian J.P Huntly, Manoj Raghavan, Farooq A Wandroo, Sahra Ali, Belinda Austen, Jacqueline Ryan, Karsten Friedrich, Nicholas C.P. Cross, PhD, Adam J Mead, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2892.
https://doi.org/10.1182/blood.V130.Suppl_1.2892.2892
Published: 2017
Journal Articles

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Clinical Trials & Observations
Claire N. Harrison, Adam J. Mead, Anesh Panchal, Sonia Fox, Christina Yap, Emmanouela Gbandi, Aimee Houlton, Samah Alimam, Joanne Ewing, Marion Wood, Frederick Chen, Jason Coppell, Nicki Panoskaltsis, Steven Knapper, Sahra Ali, Angela Hamblin, Robyn Scherber, Amylou C. Dueck, Nicholas C. P. Cross, Ruben Mesa, Mary Frances McMullin
Journal: Blood
Blood (2017) 130 (17): 1889–1897.
https://doi.org/10.1182/blood-2017-05-785790
Published: 2017
Includes: Supplemental data
Journal Articles

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Claire N. Harrison, DM, FRCP, FRCPath, Adam Mead, MD PhD, Sonia Fox, Anesh Panchal, BSc, MSc, Christina Yap, BSc, MSc, PhD, Aimee E Houlton, BSc, MSc, Samah Aliman, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Marion Wood, FRCP, FRCPath, Frederick Chen, MBBS, PhD FRCPath, Jason Coppell, Nicki Panoskaltsis, MD PhD, Steven Knapper, Sahra Ali, FRCPath, Angela Hamblin, MDPhD, Robyn M. Scherber, MD MPH, Holly Geyer, MD, Allison H Scotch, MD MPH, Amylou Constance Dueck, PhD, Nicholas CP Cross, PhD, Ruben A. Mesa, MD, Mary Frances McMullin, MD
Journal: Blood
Blood (2016) 128 (22): 1929.
https://doi.org/10.1182/blood.V128.22.1929.1929
Published: 2016
Journal Articles

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Claire N Harrison, DM, FRCP, FRCPath, Richard E Clark, MD, Joseph Chacko, Steven Knapper, DM BMBCh, John Yin, MD, Dragana Milojkovic, PhD, Mira Farquharson, FRCPath, MBChB, MRCP, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Mamta K Garg, MD, FRCP, FRCPath, Christopher Andrews, PhD, Cstat, CSci, Susan M Graham, PhD, Adam J. Mead, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 2826.
https://doi.org/10.1182/blood.V122.21.2826.2826
Published: 2013
Journal Articles

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

Clinical Trials & Observations
Alan K. Burnett, Nigel H. Russell, Ann E. Hunter, Donald Milligan, Steven Knapper, Keith Wheatley, John Yin, Mary F. McMullin, Sahra Ali, David Bowen, Robert K. Hills
Journal: Blood
Blood (2013) 122 (8): 1384–1394.
https://doi.org/10.1182/blood-2013-04-496596
Published: 2013
Journal Articles

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Alan K Burnett, MD, ChB, FRCP, FRCPath, FMedSci, Nigel H. Russell, MD, Mary Frances McMullin, MD, Jonathan Kell, MD, MB, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Paul Moreton, Andrew H Wei, MBBS, PhD, Lars Kjeldsen, MD, PhD, Robert K. Hills, MA, MSc, DPhil
Journal: Blood
Blood (2012) 120 (21): 889.
https://doi.org/10.1182/blood.V120.21.889.889
Published: 2012
Journal Articles

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Alan K Burnett, MD, Robert K Hills, MA, MSc, DPhil, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, John L Yin, MD, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Lars Kjeldsen, MD, PhD, David Bowen, Nigel H. Russell, MD
Journal: Blood
Blood (2011) 118 (21): 582.
https://doi.org/10.1182/blood.V118.21.582.582
Published: 2011